Company research
Monogram Technologies Inc.
CIK 1769759Updated Sep 24, 2026
SecurityMGRM · NASDAQ · equity
Name history
MONOGRAM ORTHOPAEDICS INC · through May 17, 2024
MGRM price & chart
Loading TradingView…
NASDAQ:MGRM on TradingView ↗About the company
Monogram Technologies (NASDAQ: MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. To learn more, visit www.monogramtechnologies.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
POS AM filing
4 filing
4 filing
4 filing
Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 17,770,000Source | 16,579,008Source | 13,690,063Source |
| Property, Plant and Equipment, NetUSD | 810,000Source | 945,020Source | 1,082,442Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 339,000Source | 548,750Source | 758,750Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,658,000Source | 13,589,028Source | 10,468,645Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 364,999Source | — |
| Assets, CurrentUSD | 16,283,000Source | 14,618,289Source | 11,256,650Source |
| Prepaid Expense and Other Assets, CurrentUSD | 625,000Source | 664,262Source | 788,004Source |
| Operating Lease, Right-of-Use AssetUSD | 338,000Source | 466,949Source | 592,221Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 3,267,000Source | 3,181,942Source | 9,540,886Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 35,000Source | 31,338Source | 9,674Source |
| Additional Paid in CapitalUSD | 82,452,000Source | 64,874,392Source | 41,894,417Source |
| Retained Earnings (Accumulated Deficit)USD | -67,988,000Source | -51,508,664Source | -37,763,447Source |
| Stockholders' Equity Attributable to ParentUSD | 14,503,000Source | 13,397,066Source | 4,149,176Source |
| Liabilities and EquityUSD | 17,770,000Source | 16,579,008Source | 13,690,063Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 1,541,000Source | 2,818,218Source | 9,048,897Source |
| Operating Lease, Liability, CurrentUSD | 138,000Source | 128,266Source | 118,166Source |
| Accounts Payable, CurrentUSD | 1,174,000Source | 2,462,268Source | 663,170Source |
| Operating Lease, Liability, NoncurrentUSD | 226,000Source | 363,724Source | 491,989Source |
| Other Liabilities, NoncurrentUSD | 1,500,000Source | — | — |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 229,000Source | 227,684Source | 748,460Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -16,328,000Source | -13,745,217Source | -13,690,947Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 430,000Source | 412,335Source | 386,686Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,174,000Source | 1,558,779Source | 743,274Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | -365,000Source | 364,999Source | — |
| Increase (Decrease) in Accounts PayableUSD | -1,289,000Source | 1,799,098Source | 214,138Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,968,000Source | -13,542,509Source | -8,419,553Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -84,000Source | -64,913Source | -241,203Source |
| Cash flows from financing activities: | |||
| Payments for Repurchase of Common StockUSD | 200,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 16,121,000Source | 16,727,805Source | 13,593,691Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,069,000Source | 3,120,383Source | 4,932,935Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 15,658,000Source | 13,589,028Source | 10,468,645Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | — | 1,558,779Source | 743,274Source |
| Amortization of Intangible AssetsUSD | 210,000Source | 210,000Source | 210,000Source |
| DepreciationUSD | 220,000Source | 202,335Source | 176,686Source |
| General and Administrative ExpenseUSD | 4,412,000Source | 4,052,755Source | 2,484,750Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 526,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -16,328,000Source | -13,745,217Source | -13,690,947Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -16,479,000Source | — | — |
| Nonoperating Income (Expense)USD | -1,018,000Source | 3,522,812Source | -3,077,800Source |
| Operating ExpensesUSD | 15,310,000Source | 17,633,028Source | 10,613,147Source |
| Operating Lease, ExpenseUSD | 136,000Source | 140,654Source | 134,641Source |
| Proceeds from Issuance of Common StockUSD | 5,191,000Source | 15,330,763Source | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Total RevenueUSD | — | 364,999Source | — |
| Operating Income (Loss)USD | -15,310,000Source | -17,268,029Source | -10,613,147Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -16,328,000Source | -13,745,217Source | -13,690,947Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -16,328,000Source | -13,745,217Source | -13,690,947Source |
| Earnings Per Share, BasicUSD per share | -0.51Source | -0.61Source | -1.42Source |
| Earnings Per Share, DilutedUSD per share | -0.51Source | -0.61Source | -1.42Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 32,571,470Source | 22,409,222Source | 9,673,870Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 32,571,470Source | 22,409,222Source | 9,673,870Source |
| Additional Financial Items | |||
| Amortization of Intangible AssetsUSD | 210,000Source | 210,000Source | 210,000Source |
| General and Administrative ExpenseUSD | 4,412,000Source | 4,052,755Source | 2,484,750Source |
| Interest and Other IncomeUSD | — | 434,279Source | 98,065Source |
| Investment Income, InterestUSD | 526,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -16,479,000Source | — | — |
| Nonoperating Income (Expense)USD | -1,018,000Source | 3,522,812Source | -3,077,800Source |
| Operating ExpensesUSD | 15,310,000Source | 17,633,028Source | 10,613,147Source |
| Operating Lease, ExpenseUSD | 136,000Source | 140,654Source | 134,641Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 151,000Source | — | — |
| Research and Development ExpenseUSD | 8,790,000Source | 10,585,884Source | 5,384,710Source |
| Selling and Marketing ExpenseUSD | 2,108,000Source | 2,994,389Source | 2,743,687Source |
Filing attachments
tm2527971d1_ex99-1.htm · 8-K · 2025-10-07
EX-99.1 6 tm2527971d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Zimmer Biomet Completes Acquisition of Monogram Technologies Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for orthopedic procedures (WARSAW, Ind.) October 7, 2025 - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (“Zimmer Biomet”), a global medical technology leader, today announced it has compl…
Read attachment ↗tm2524795d1_ex99-1.htm · 8-K · 2025-08-29
EX-99.1 2 tm2524795d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Text Message Target Audience: Registered Holders ACTION REQUESTED - The Monogram Technologies 2025 Special Meeting of Stockholders to approve the acquisition by Zimmer Biomet, is scheduled for September 30th. Please vote your shares now at monogram.vote Please vote on Monogram's acquisition by Zimmer Biomet. Submit your vote now at monogram.vote
Read attachment ↗tm2524795d1_ex99-2.htm · 8-K · 2025-08-29
EX-99.2 3 tm2524795d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Target Audience: Street Holders ACTION REQUESTED - The Monogram Technologies 2025 Special Meeting of Stockholders to approve the acquisition by Zimmer Biomet, is scheduled for September 30th. Please call (888) 785-6673 now to vote your shares.
Read attachment ↗tm2522118d3_ex99-1.htm · 8-K · 2025-07-31
EX-99.1 2 tm2522118d3_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Monogram Acquisition by Zimmer Biomet FAQs Available Here: https://www.monogramtechnologies.com/investors
Read attachment ↗tm2522118d1_ex99-1.htm · 8-K · 2025-07-30
EX-99.1 2 tm2522118d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Dear Shareholders, We’ve added a Frequently Asked Questions (FAQ) section to our Investor Relations page to address many of the questions we’ve been receiving about the transaction, including the structure of the CVR and the total potential consideration. You can view the FAQ here: https://www.monogramtechnologies.com/investors We encourage all shareholders to review this information for clarity on the transaction terms and timi…
Read attachment ↗tm2521919d1_ex99-1.htm · 8-K · 2025-07-29
EX-99.1 2 tm2521919d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Monogram Technologies Announces World’s First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery The Procedure Utilized Monogram’s mBôs TKA System Performed in India with Shalby Hospitals Groundbreaking Procedure Delivers the World’s First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient AUSTIN, TX - July 29, 2025 - Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics c…
Read attachment ↗